Concepts (106)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Central Nervous System Neoplasms | 10 | 2026 | 210 | 4.940 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 4 | 2026 | 92 | 2.610 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2026 | 1265 | 1.780 |
Why?
|
| Testicular Neoplasms | 3 | 2026 | 112 | 1.570 |
Why?
|
| Cerebellar Neoplasms | 2 | 2026 | 316 | 1.410 |
Why?
|
| Medulloblastoma | 2 | 2026 | 376 | 1.370 |
Why?
|
| Brain Neoplasms | 4 | 2023 | 1304 | 1.100 |
Why?
|
| Re-Irradiation | 1 | 2026 | 5 | 0.960 |
Why?
|
| Germinoma | 2 | 2023 | 29 | 0.950 |
Why?
|
| Immunological Synapses | 1 | 2025 | 32 | 0.850 |
Why?
|
| Membrane Microdomains | 1 | 2025 | 60 | 0.850 |
Why?
|
| Cochlea | 1 | 2024 | 85 | 0.830 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 126 | 0.820 |
Why?
|
| Proton Therapy | 1 | 2024 | 155 | 0.750 |
Why?
|
| Cisplatin | 1 | 2024 | 274 | 0.750 |
Why?
|
| Hearing Loss | 1 | 2024 | 203 | 0.730 |
Why?
|
| Precursor Cells, T-Lymphoid | 1 | 2022 | 1 | 0.730 |
Why?
|
| Combined Modality Therapy | 5 | 2026 | 1212 | 0.660 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 90 | 0.650 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2022 | 163 | 0.640 |
Why?
|
| Medical Oncology | 2 | 2021 | 243 | 0.640 |
Why?
|
| Pinealoma | 1 | 2020 | 20 | 0.630 |
Why?
|
| Pineal Gland | 1 | 2020 | 21 | 0.630 |
Why?
|
| Radiation, Ionizing | 1 | 2019 | 38 | 0.590 |
Why?
|
| Telecommunications | 1 | 2018 | 21 | 0.570 |
Why?
|
| Remote Consultation | 1 | 2018 | 23 | 0.560 |
Why?
|
| Head | 1 | 2019 | 113 | 0.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 1324 | 0.550 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2020 | 260 | 0.550 |
Why?
|
| Carcinoma, Embryonal | 1 | 2017 | 1 | 0.540 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 54 | 0.540 |
Why?
|
| Rhabdoid Tumor | 1 | 2017 | 46 | 0.520 |
Why?
|
| Immunoconjugates | 1 | 2017 | 41 | 0.520 |
Why?
|
| Betacoronavirus | 1 | 2020 | 273 | 0.520 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 283 | 0.510 |
Why?
|
| Neurology | 1 | 2018 | 116 | 0.500 |
Why?
|
| Teratoma | 1 | 2017 | 120 | 0.490 |
Why?
|
| Placenta | 1 | 2020 | 500 | 0.480 |
Why?
|
| Prognosis | 5 | 2026 | 4866 | 0.480 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 339 | 0.460 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 349 | 0.460 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2020 | 503 | 0.450 |
Why?
|
| Down Syndrome | 1 | 2017 | 233 | 0.430 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 881 | 0.420 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 420 | 0.390 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 1815 | 0.370 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 1278 | 0.360 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2063 | 0.340 |
Why?
|
| Follow-Up Studies | 3 | 2026 | 5187 | 0.320 |
Why?
|
| Humans | 18 | 2026 | 130534 | 0.310 |
Why?
|
| Child | 7 | 2026 | 26263 | 0.300 |
Why?
|
| Pediatrics | 1 | 2018 | 1248 | 0.290 |
Why?
|
| Retrospective Studies | 6 | 2026 | 17634 | 0.270 |
Why?
|
| Survival Rate | 2 | 2026 | 2110 | 0.270 |
Why?
|
| Adolescent | 5 | 2026 | 20889 | 0.260 |
Why?
|
| Young Adult | 3 | 2026 | 10037 | 0.240 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2025 | 25 | 0.220 |
Why?
|
| CD28 Antigens | 1 | 2025 | 76 | 0.220 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2025 | 272 | 0.200 |
Why?
|
| Chemoradiotherapy | 1 | 2024 | 125 | 0.200 |
Why?
|
| Female | 8 | 2024 | 70545 | 0.180 |
Why?
|
| Spinal Cord | 1 | 2023 | 255 | 0.180 |
Why?
|
| Chile | 1 | 2021 | 25 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 399 | 0.170 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 3812 | 0.160 |
Why?
|
| alpha-Fetoproteins | 1 | 2021 | 125 | 0.160 |
Why?
|
| Immunotherapy | 1 | 2026 | 760 | 0.160 |
Why?
|
| Nasopharynx | 1 | 2020 | 88 | 0.160 |
Why?
|
| In Situ Hybridization | 1 | 2020 | 437 | 0.150 |
Why?
|
| Central Nervous System | 1 | 2021 | 269 | 0.150 |
Why?
|
| Thrombosis | 1 | 2024 | 498 | 0.150 |
Why?
|
| Adult | 3 | 2026 | 31114 | 0.150 |
Why?
|
| Latin America | 1 | 2018 | 108 | 0.140 |
Why?
|
| Age Factors | 1 | 2024 | 2822 | 0.130 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2017 | 38 | 0.130 |
Why?
|
| Adrenalectomy | 1 | 2017 | 30 | 0.130 |
Why?
|
| Ki-1 Antigen | 1 | 2017 | 31 | 0.130 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 99 | 0.130 |
Why?
|
| Infratentorial Neoplasms | 1 | 2017 | 32 | 0.130 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2017 | 35 | 0.130 |
Why?
|
| Male | 5 | 2026 | 64613 | 0.130 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2025 | 955 | 0.130 |
Why?
|
| Cell Line, Tumor | 1 | 2025 | 3727 | 0.130 |
Why?
|
| Nephrectomy | 1 | 2017 | 156 | 0.120 |
Why?
|
| Child, Preschool | 2 | 2024 | 15045 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2025 | 1714 | 0.120 |
Why?
|
| Infant | 3 | 2024 | 13318 | 0.110 |
Why?
|
| Internet | 1 | 2018 | 420 | 0.110 |
Why?
|
| Survivors | 1 | 2017 | 345 | 0.110 |
Why?
|
| Disease Management | 1 | 2019 | 556 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 1116 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2025 | 4664 | 0.090 |
Why?
|
| Infant, Newborn | 2 | 2024 | 8626 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2020 | 6424 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 4058 | 0.070 |
Why?
|
| Pregnancy | 1 | 2020 | 7459 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3752 | 0.060 |
Why?
|
| Animals | 1 | 2026 | 33726 | 0.050 |
Why?
|
| Thrombectomy | 1 | 2024 | 117 | 0.050 |
Why?
|
| Thrombolytic Therapy | 1 | 2024 | 191 | 0.050 |
Why?
|
| Aortic Diseases | 1 | 2024 | 187 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2017 | 12846 | 0.040 |
Why?
|
| Basal Ganglia | 1 | 2021 | 60 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2021 | 217 | 0.040 |
Why?
|
| Thalamus | 1 | 2021 | 93 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2024 | 601 | 0.040 |
Why?
|